Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-β gene therapy for malignant glioma in an experimental mouse intracranial glioma

✍ Scribed by Ryuta Saito; Masaaki Mizuno; Norimoto Nakahara; Takaya Tsuno; Toshihiro Kumabe; Takashi Yoshimoto; Jun Yoshida

• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: French
• Weight: 372 KB
• Volume: 111
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.20331

✦ Synopsis

Abstract

Interferon‐β (IFN‐β) has been used as an antitumor drug against human glioma, melanoma and medulloblastoma since the 1980s. Recently, we developed a new gene therapy using the IFN‐β gene against malignant gliomas and then began clinical trials in 2000. Since stimulation of immune system was one mechanism of antitumor effect induced by IFN‐β gene therapy, we hypothesized that combination of IFN‐β gene therapy with immunotherapy might increase its effectiveness. In the present study, we tested whether combination therapy with IFN‐β gene therapy and immunotherapy using tumor cell lysate‐pulsed dendritic cells (DCs) would increase the efficacy of IFN‐β gene therapy. In an experimental mouse intracranial glioma (GL261), which cannot be cured by either IFN‐β gene therapy or DC immunotherapy alone, IFN‐β gene therapy following DC immunotherapy resulted in a significant prolongation in survival of the mice. Moreover, when this combination was performed twice, 50% of treated mice survived longer than 100 days. Considering these results, this combination therapy may be one promising candidate for glioma therapy in the near future. © 2004 Wiley‐Liss, Inc.